Cell BioEngines
Cell BioEngines, Inc.: A clinical-stage biotech firm innovating cancer cures with scalable cell therapies.
Operating headquarters
New York City, NY, USFounded
2022Cell BioEngines, Inc.: A clinical-stage biotech firm innovating cancer cures with scalable cell therapies.
Founded with a mission to cure cancer, Cell BioEngines, Inc. is a clinical-stage biotech company specializing in "off-the-shelf" allogenic cell therapies. Utilizing its proprietary Stem-SPACE platform technology, the company aims to produce clinical-grade cells at scale, making advanced immunotherapy treatments more accessible. Their market focus is on pre-clinical and clinical-stage cancer therapies, targeting a wide range of malignancies with innovative cell-based solutions.
Notable figures affiliated with Cell BioEngines include leading experts in biotechnology and oncology, although specific names are not provided. The company has attracted significant interest from investors in the biotech sector due to its groundbreaking approach and potential for high impact. Key achievements include the successful development and scaling of their Stem-SPACE platform, positioning them as a promising player in the fight against cancer. Their work has the potential to revolutionize cancer treatment by offering more effective and readily available therapeutic options.
Companies similar to Cell BioEngines include Appia Bio, Xcell Biosciences, Catamaran Bio and Platelet BioGenesis.
Cell BioEngines was founded in 2022.
Cell BioEngines' headquarters is located in New York City, NY, US.
Cell BioEngines' most recent funding round was for $250k (USD) in August 2023.
As of Aug 11, 2023, Cell BioEngines has disclosed funding of $625k (USD). Undisclosed round amounts are excluded.
Cell BioEngines has 6 employees as of Feb 4, 2024.
Platelet BioGenesis
